Search Results
May 14, 2026, 09:00 ET A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Avaí Bio's Cell-Based Platform Approach
reference point on the broader aging-biology therapeutics universe that Avaí Bio's α-Klotho program sits within.CRISPR Therapeutics AG (NASDAQ: CRSP) has continued to expand its CRISPR/Cas9 gene-editing platform across multiple therapeutic verticals — including the autologous and allogeneic cell
More news about: Equity Insider
Apr 29, 2026, 09:00 ET Vanguard to Update Names of U.S. Equity Index Funds Tracking Morningstar Indexes
VALLEY FORGE, Pa., April 29, 2026 /PRNewswire/ -- Following Morningstar's rebranding of the CRSP Market Indexes to Morningstar Indexes, Vanguard today announced upcoming changes to the names of multiple Vanguard U.S. equity index funds tracking
More news about: Vanguard
Mar 24, 2026, 11:05 ET Anti-Aging Protein Research Takes a Step Forward with Cell Cloning
(NASDAQ: VRTX) demonstrated what that looks like at scale. The company's gene-edited cell therapy Casgevy — developed with CRISPR Therapeutics (NASDAQ: CRSP) — became the world's first approved CRISPR-based treatment, now available for sickle cell disease and transfusion-dependent beta-thalassemia. Vertex
More news about: Equity Insider
Feb 25, 2026, 09:00 ET Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
forefront of this expansion include Oncolytics Biotech (NASDAQ: ONCY), ImmunityBio (NASDAQ: IBRX), CRISPR Therapeutics (NASDAQ: CRSP), BioNTech (NASDAQ: BNTX), and Novocure (NASDAQ: NVCR).
More news about: Equity Insider
Jan 02, 2026, 13:29 ET Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize
pipelines of Avant Technologies, Inc. (OTCQB: AVAI), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), CRISPR Therapeutics (NASDAQ: CRSP), Prime Medicine, Inc. (NASDAQ: PRME), and Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL).
More news about: Equity Insider
Dec 09, 2025, 11:57 ET Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
convergence include Avant Technologies, Inc. (OTCQB: AVAI), Beam Therapeutics Inc. (NASDAQ: BEAM), CRISPR Therapeutics (NASDAQ: CRSP), Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), and Schrödinger, Inc. (NASDAQ: SDGR).
More news about: Equity Insider
Sep 18, 2025, 08:45 ET Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
markets this week include: Avant Technologies Inc. (OTCQB: AVAI), Tempus AI, Inc. (NASDAQ: TEM), CRISPR Therapeutics (NASDAQ: CRSP), BioNTech SE (NASDAQ: BNTX), Bristol Myers Squibb Company (NYSE: BMY).
More news about: MarketNewsUpdates
Jul 09, 2025, 08:30 ET Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
including Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), ImmunityBio Inc. (NASDAQ: IBRX), Crispr Therapeutics AG (NASDAQ: CRSP) and CytomX Therapeutics Inc. (NASDAQ: CTMX).
More news about: NetworkNewsWire